Complications of Oral Anticoagulant Therapy (Bleeding and Nonbleeding: Rates and Risk Factors)

Seminars in Vascular Medicine

Volumn 3, Issue 3, 2003, Pages 271-278

  Hylek, Elaine M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hemorrhage; Intracranial hemorrhage; Oral anticoagulant; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; COUMARIN; CYTOCHROME P450 2C9; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ANAMNESIS; ANTICOAGULATION; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; COMORBIDITY; DRUG METABOLISM; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; INTERNATIONAL STANDARD UNIT; LEUKOARAIOSIS; PURPLE TOES SYNDROME; REVIEW; RISK FACTOR; SKIN DISEASE; SKIN NECROSIS; VASCULAR AMYLOIDOSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CEREBRAL HEMORRHAGE; HEMORRHAGE; HUMANS; RISK FACTORS; WARFARIN;

EID: 0142135449     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44463     Document Type: Review

References (63)

1. Graafsma YP, Prins MH, Lensing WA, et al. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost 1997;78:1189-1192
2. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989;42:711-718
3. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-99
4. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-687
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults-national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
6. Franke CL, De Jonge J, van Swieten JC, et al. Intracerebral hematomas during anticoagulant treatment. Stroke 1990;21:726-730
7. Wintzen AR, de Jonge H, Loeliger EA, et al. The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984;16:533-558
8. Forsting M, Mattle HP, Huber P. Anticoagulation-related intracerebral hemorrhage. Cerebrovasc Dis 1991;1:97-102
9. Fogelholm R, Eskola K, Kiminkinen T, et al. Anticoagulant treatment as a risk factor for primary intracerebral hemorrhage. J Neurol Neurosurg Psych 1992;55:1121-1124
10. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902
11. Rosand J, Hylek EM, O'Donnell HC, et al. Warfarin-associated hemorrhage and cerebral amyloid angiopathy. Neurology 2000;55:947-951
12. Radberg JA, Olsson JE, Radberg CT. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke 1991;22:571-576
13. Stroke Prevention in Reversible Ischemia Trial Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-865
14. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-1327
15. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416
16. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-152
17. Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke 1995;26:1471-1477
18. Manolio TA, Kronmal RA, Burke GL, et al. Magnetic resonance abnormalities and cerebrovascular disease in older adults: the Cardiovascular Health Study. Stroke 1994;25:318-327
19. Smith EE, Rosand J, Knudsen KA, et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002;59:193-197
20. van Swieten JC, Hijdra A, Koudstaal PJ, et al. Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psych 1990;53:1080-1083
21. Okazaki H, Reagan TJ, Campbell RJ. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc 1979;54:22-31
22. Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987;18:311-324
23. Greenberg SM, O'Donnell HC, Schaefer PW, et al. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology 1999;53:1135-1138
24. Roob G, Schmidt R, Kapellar P, et al. MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology 1999;52:991-994
25. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119(suppl):194S-206S
26. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457
27. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;1:499-503
28. Smith P, Arneson H, Holme I. The effect of warfarin on mortality and re-infarction after myocardial infarction. N Engl J Med 1990;323:147-152
29. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638
30. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562
31. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multi-center study. Ann Intern Med 1993;118:511-520
32. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428
33. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice. Arch Intern Med 2001;161:1443-1447
34. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-683
35. Hylek EM, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662
36. Hylek EM, Chang Y, Skates SJ, et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-1617
37. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996;124:970-979
38. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin. Ann Intern Med 1992;116:901-904
39. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992;45:704-706
40. Wynne HA, Kamali F, Edwards C, et al. Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing 1996;25:429-432
41. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatric Med 2001;17:1-13
42. Hylek EM, Regan S, Go AS, et al. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med 2001;135:393-400
43. Aithal GP, Day CP, Kesteven PJL, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-719
44. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-1698
45. Pettiti DB, Strom BL, Melmon KL. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 1986;81:255-259
46. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136
47. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J 1984;288:1268-1270
48. Roberts GW, Druskeit T, Jorgensen LE, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust NZ J Med 1999;29:731-736
49. Gedge J, Orme S, Hampton KK, et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000;29:31-34
50. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994;35:464-466
51. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-263
52. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;115:787-796
53. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993;153:1665-1670
54. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2001:2051,2484
55. Tincani E, Bertoni G, Silingardi M, et al. Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients. Am J Med 2000;108:165-167
56. Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-432
57. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982;307:1676-1681
58. Altman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991;101:427-431
59. Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-1245
60. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-1647
61. Wilt VM, Gums JG, Ahmed OI, et al. Pharmacy operated anticoagulation service: improved outcomes in patients on warfarin. Pharmacotherapy 1995;15:732-779
62. Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993;129:766-768
63. Devereaux PJ, Anderson DR, Gardner MJ, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J 2001;323:1-7